- Home
- SKIN vs GANX Comparison
SKIN vs GANX Comparison
Compare SKIN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | GANX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 159.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKIN | GANX |
|---|---|---|
| Price | $1.29 | $1.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.00 | ★ $8.00 |
| AVG Volume (30 Days) | 446.4K | ★ 902.6K |
| Earning Date | 03-11-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $301,917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $1.41 |
| 52 Week High | $2.69 | $4.34 |
Technical Indicators
Market Signals| Indicator | SKIN | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 31.91 |
| Support Level | $1.39 | $1.93 |
| Resistance Level | $1.55 | $2.07 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.50 | 4.25 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.